PL3079675T3 - Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid do zastosowania w korzystnym wpływaniu na poziom lipidów we krwi poprzez modyfikowanie mikrobioty jelitowej - Google Patents
Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid do zastosowania w korzystnym wpływaniu na poziom lipidów we krwi poprzez modyfikowanie mikrobioty jelitowejInfo
- Publication number
- PL3079675T3 PL3079675T3 PL14809908T PL14809908T PL3079675T3 PL 3079675 T3 PL3079675 T3 PL 3079675T3 PL 14809908 T PL14809908 T PL 14809908T PL 14809908 T PL14809908 T PL 14809908T PL 3079675 T3 PL3079675 T3 PL 3079675T3
- Authority
- PL
- Poland
- Prior art keywords
- nicotinamide
- modifying
- pharmaceutical composition
- composition containing
- nicotinic acid
- Prior art date
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 3
- 235000005152 nicotinamide Nutrition 0.000 title 2
- 239000011570 nicotinamide Substances 0.000 title 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 244000005709 gut microbiome Species 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 229960003966 nicotinamide Drugs 0.000 title 1
- 229960003512 nicotinic acid Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13197283 | 2013-12-13 | ||
| EP14154543 | 2014-02-10 | ||
| EP14809908.8A EP3079675B1 (en) | 2013-12-13 | 2014-12-12 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide for use in beneficially influencing blood lipid levels by modifying the intestinal microbiota |
| PCT/EP2014/077646 WO2015086843A2 (en) | 2013-12-13 | 2014-12-12 | A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3079675T3 true PL3079675T3 (pl) | 2020-07-27 |
Family
ID=52021224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14809908T PL3079675T3 (pl) | 2013-12-13 | 2014-12-12 | Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid do zastosowania w korzystnym wpływaniu na poziom lipidów we krwi poprzez modyfikowanie mikrobioty jelitowej |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10888555B2 (pl) |
| EP (1) | EP3079675B1 (pl) |
| JP (2) | JP6895752B2 (pl) |
| DK (1) | DK3079675T3 (pl) |
| ES (1) | ES2788866T3 (pl) |
| HU (1) | HUE048488T2 (pl) |
| PL (1) | PL3079675T3 (pl) |
| PT (1) | PT3079675T (pl) |
| WO (1) | WO2015086843A2 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2716115T3 (es) | 2013-12-13 | 2019-06-10 | Conaris Res Institute Ag | Una composición farmacéutica que contiene conbinaciones de nicotinamida y ácido 5-aminosalicílico para influir de forma beneficiosa en la microbiota intestinal y/o tratar la inflamación gastrointestinal |
| CN109310642B (zh) | 2016-04-19 | 2021-07-20 | 费灵有限公司 | 美沙拉嗪的口服药物组合物 |
| ES2848575T3 (es) * | 2016-04-19 | 2021-08-10 | Conaris Res Institute Ag | Composiciones farmacéuticas orales de nicotinamida |
| TWI736635B (zh) | 2016-06-13 | 2021-08-21 | 心悅生醫股份有限公司 | 苯甲酸鋰之共晶及其用途 |
| KR102403048B1 (ko) * | 2016-06-13 | 2022-05-26 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | 벤조산나트륨의 공-결정 및 그의 용도 |
| JPWO2018198842A1 (ja) * | 2017-04-23 | 2020-04-23 | 国立大学法人九州大学 | 非アルコール性脂肪性肝疾患用治療剤 |
| EP3398601A1 (en) * | 2017-05-02 | 2018-11-07 | Salmon Pharma GmbH | Nicotinamide for treating dyslipidemia |
| EP3398600A1 (en) * | 2017-05-02 | 2018-11-07 | Salmon Pharma GmbH | Modified release nicotinamide |
| EP3703690A1 (en) * | 2017-10-30 | 2020-09-09 | Unilever N.V. | Use of niacinamide for microbiome balancing |
| US20220249535A1 (en) * | 2019-04-05 | 2022-08-11 | Rejuvenation Therapeutics | Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof |
| CN113893262A (zh) * | 2021-09-29 | 2022-01-07 | 武汉英纽林生物科技有限公司 | 一种用于干预糖尿病前期空腹血糖偏高的nad+组合物及其制备方法和使用方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5736532A (en) | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
| GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| US6713057B1 (en) * | 1999-02-24 | 2004-03-30 | The Johns Hopkins University | Compositions and methods for modulating serum cholesterol |
| GB0015242D0 (en) | 2000-06-22 | 2000-08-16 | Nycomed Amersham Plc | Stabiliser for radiopharmaceuticals |
| WO2002011725A1 (en) | 2000-08-08 | 2002-02-14 | Shionogi & Co., Ltd. | Inflammatory cytokine production inhibitors |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| US7417037B2 (en) | 2004-01-20 | 2008-08-26 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| US20060264409A1 (en) | 2004-01-20 | 2006-11-23 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| WO2005115075A2 (en) | 2004-05-27 | 2005-12-08 | Antibe Therapeutics Inc. | Salt of 4- or 5- aminosalicylic acid |
| CA2581816A1 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
| JPWO2007004613A1 (ja) | 2005-07-01 | 2009-01-29 | 味の素株式会社 | 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤 |
| ITMI20061932A1 (it) | 2006-10-09 | 2008-04-10 | Carlo Ghisalberti | Complessi a trasferimento di carica per uso medicale |
| US20090104171A1 (en) | 2007-10-19 | 2009-04-23 | Pardee Joel D | Metabolic Enhancement Therapy |
| EP2276491A4 (en) | 2008-04-25 | 2011-08-17 | Karolinska Inst Innovations Ab | NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME |
| MX2010013169A (es) * | 2008-06-02 | 2010-12-21 | Reddy S Lab Ltd | Formulaciones de niacina de liberacion modificada. |
| WO2010040113A1 (en) | 2008-10-03 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
| JP2011121889A (ja) | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP2012102054A (ja) | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | 腸内ポリアミン増強剤 |
| WO2012090224A1 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug |
| CA2876540C (en) | 2012-06-15 | 2022-11-29 | Conaris Research Institute Ag | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| US10456389B2 (en) | 2013-06-14 | 2019-10-29 | Conaris Research Institute Ag | Extended release nicotinamide formulation |
| ES2716115T3 (es) | 2013-12-13 | 2019-06-10 | Conaris Res Institute Ag | Una composición farmacéutica que contiene conbinaciones de nicotinamida y ácido 5-aminosalicílico para influir de forma beneficiosa en la microbiota intestinal y/o tratar la inflamación gastrointestinal |
| ES2848575T3 (es) | 2016-04-19 | 2021-08-10 | Conaris Res Institute Ag | Composiciones farmacéuticas orales de nicotinamida |
-
2014
- 2014-12-12 JP JP2016538751A patent/JP6895752B2/ja active Active
- 2014-12-12 US US15/103,410 patent/US10888555B2/en active Active
- 2014-12-12 EP EP14809908.8A patent/EP3079675B1/en active Active
- 2014-12-12 ES ES14809908T patent/ES2788866T3/es active Active
- 2014-12-12 PL PL14809908T patent/PL3079675T3/pl unknown
- 2014-12-12 WO PCT/EP2014/077646 patent/WO2015086843A2/en not_active Ceased
- 2014-12-12 DK DK14809908.8T patent/DK3079675T3/da active
- 2014-12-12 PT PT148099088T patent/PT3079675T/pt unknown
- 2014-12-12 HU HUE14809908A patent/HUE048488T2/hu unknown
-
2019
- 2019-06-03 JP JP2019103443A patent/JP7387299B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7387299B2 (ja) | 2023-11-28 |
| US20170027924A1 (en) | 2017-02-02 |
| EP3079675A2 (en) | 2016-10-19 |
| EP3079675B1 (en) | 2020-02-12 |
| JP2017500311A (ja) | 2017-01-05 |
| JP6895752B2 (ja) | 2021-06-30 |
| HUE048488T2 (hu) | 2020-07-28 |
| ES2788866T3 (es) | 2020-10-23 |
| PT3079675T (pt) | 2020-03-05 |
| JP2019189616A (ja) | 2019-10-31 |
| US10888555B2 (en) | 2021-01-12 |
| WO2015086843A2 (en) | 2015-06-18 |
| DK3079675T3 (da) | 2020-04-20 |
| WO2015086843A3 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE048488T2 (hu) | Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával | |
| IL236205A0 (en) | A pharmaceutical composition containing nicotinic acid and/or nicotamide and/or tryptophan to have a positive effect on the intestinal microbiota | |
| ZA201406233B (en) | Pharmaceutical composition and administration thereof | |
| IL238575A0 (en) | Systems and methods for administering drugs to the lung | |
| PL2940014T3 (pl) | Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna | |
| IL240496B (en) | History of pyridine, process for their preparation, pharmaceutical preparations containing them and their use in medicine | |
| IL238060B (en) | 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them | |
| ZA201601304B (en) | A stable pharmaceutical composition containing amlodipine and valsartan | |
| ZA201603629B (en) | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation | |
| IL245415A0 (en) | A process for the preparation of methylphenidate and its pharmaceutical salts | |
| ZA201501095B (en) | Pyridine derivative and medicine | |
| PT2789607T (pt) | Derivado de piridona e medicamento contendo o mesmo | |
| SG11201406942SA (en) | Trans-2-decenoic acid derivative and drug containing same | |
| PL2931716T3 (pl) | Pochodne pirydonu i ich zastosowanie w leczeniu gruźlicy | |
| EP2687523A4 (en) | NEW PHENYLPYRIDINE DERIVATIVE AND MEDICAMENT THEREFOR | |
| IL234614B (en) | Pharmaceutical composition and preparation method thereof | |
| SG11201501043TA (en) | Pharmaceutical composition for oral administration with improved dissolution and/or absorption | |
| ZA201408723B (en) | Emulsion for pharmaceutical use and method for the production thereof | |
| EP3071195A4 (en) | Regimen and method for treatment of type 2 diabetes | |
| TH1401007439A (th) | องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้ | |
| AU2013904467A0 (en) | Regimen and method for treatment of type 2 diabetes | |
| HUP1300648A2 (hu) | Dabigatran és származékainak komplexei,elõállításuk és gyógyszerészeti kompozícióik |